Literature DB >> 19324004

Reduced lipid oxidation in myotubes established from obese and type 2 diabetic subjects.

Michael Gaster1.   

Abstract

To date, it is unknown whether reduced lipid oxidation of skeletal muscle of obese and obese type 2 diabetic (T2D) subjects partly is based on reduced oxidation of endogenous lipids. Palmitate (PA) accumulation, total oxidation and lipolysis were not different between myotubes established from lean, obese and T2D subjects, chronic exposed for PA. Complete oxidation from endogenous PA was reduced in diabetic and obese compared to lean myotubes while exogenous PA oxidation was reduced in diabetic compared to lean myotubes. The complete/incomplete ratio was significantly reduced in diabetic myotubes both for endogenous and exogenous lipids. Thus myotubes established from obese and obese T2D subjects express a reduced complete oxidation of endogenous lipids. Two cardinal principles govern the reduced lipid oxidation in obese and diabetic myotubes; firstly, an impaired coupling between endogenous lipid and mitochondria in obese and obese diabetic myotubes and secondly, a mismatch between beta-oxidation and citric acid cycle in obese diabetic myotubes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19324004     DOI: 10.1016/j.bbrc.2009.03.102

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Angiotensin inhibition and longevity: a question of hydration.

Authors:  Simon N Thornton
Journal:  Pflugers Arch       Date:  2010-12-17       Impact factor: 3.657

2.  Characterization of human myotubes from type 2 diabetic and nondiabetic subjects using complementary quantitative mass spectrometric methods.

Authors:  Tine E Thingholm; Steffen Bak; Henning Beck-Nielsen; Ole N Jensen; Michael Gaster
Journal:  Mol Cell Proteomics       Date:  2011-06-22       Impact factor: 5.911

3.  Mitochondrial lipid oxidation is impaired in cultured myotubes from obese humans.

Authors:  K E Boyle; D Zheng; E J Anderson; P D Neufer; J A Houmard
Journal:  Int J Obes (Lond)       Date:  2011-10-25       Impact factor: 5.095

4.  Effect of serial cell passaging in the retention of fiber type and mitochondrial content in primary human myotubes.

Authors:  Jeffrey D Covington; Cassandra K Myland; Arild C Rustan; Eric Ravussin; Steven R Smith; Sudip Bajpeyi
Journal:  Obesity (Silver Spring)       Date:  2015-11-05       Impact factor: 5.002

5.  Reduced incorporation of fatty acids into triacylglycerol in myotubes from obese individuals with type 2 diabetes.

Authors:  Lauren M Sparks; Madeleen Bosma; Matthijs K C Hesselink; Patrick Schrauwen; Bram Brouwers; Tineke van de Weijer; Lena Bilet; Gert Schaart; Esther Moonen-Kornips; Thomas O Eichmann; Achim Lass
Journal:  Diabetes       Date:  2014-01-31       Impact factor: 9.461

6.  Reduced TCA Flux in Diabetic Myotubes: Determined by Single Defects?

Authors:  Michael Gaster
Journal:  Biochem Res Int       Date:  2012-03-18

7.  Insulin resistance is not conserved in myotubes established from women with PCOS.

Authors:  Mette Eriksen; Ann Dorte Pørneki; Vibe Skov; Jorge S Burns; Henning Beck-Nielsen; Dorte Glintborg; Michael Gaster
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

8.  FA1 Induces Pro-Inflammatory and Anti-Adipogenic Pathways/Markers in Human Myotubes Established from Lean, Obese, and Type 2 Diabetic Subjects but Not Insulin Resistance.

Authors:  Basem M Abdallah; Henning Beck-Nielsen; Michael Gaster
Journal:  Front Endocrinol (Lausanne)       Date:  2013-04-05       Impact factor: 5.555

9.  Simultaneous quantification of salivary 3-hydroxybutyrate, 3-hydroxyisobutyrate, 3-hydroxy-3-methylbutyrate, and 2-hydroxybutyrate as possible markers of amino acid and fatty acid catabolic pathways by LC-ESI-MS/MS.

Authors:  Teruo Miyazaki; Akira Honda; Tadashi Ikegami; Junichi Iwamoto; Tadakuni Monma; Takeshi Hirayama; Yoshifumi Saito; Kouwa Yamashita; Yasushi Matsuzaki
Journal:  Springerplus       Date:  2015-09-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.